This analysis is generated by AI. It may be incomplete or inaccurate—please verify before acting.
AI-Powered Technical Due Diligence for VCs
A SaaS platform that automates deep technical due diligence for investors by cross-referencing startup pitch claims against scientific literature, patents, and clinical trial registries. It flags discrepancies and scores technical risk to prevent funding of companies making unverifiable scientific claims.
これが重要な理由
You are a partner at a venture capital firm evaluating a deep-tech or biotech startup. The founders present compelling pitch decks with impressive scientific claims, but you lack the specialized expertise to independently verify whether their technology actually works. Your in-house analysts focus on financial models and market sizing, not scientific feasibility. You fear falling victim to another high-profile fraud case where investors poured hundreds of millions into a company whose core technology was fundamentally flawed. You need a way to rapidly and objectively assess technical risk before committing capital.
- · Venture capital firms, family offices, and angel investors evaluating deep-tech, biotech, and hard-tech startups向けに構築。
- · 最も可能性の高い収益化モデル: SaaS subscription。
痛み · ナラティブ
You are a partner at a venture capital firm evaluating a deep-tech or biotech startup. The founders present compelling pitch decks with impressive scientific claims, but you lack the specialized expertise to independently verify whether their technology actually works. Your in-house analysts focus on financial models and market sizing, not scientific feasibility. You fear falling victim to another high-profile fraud case where investors poured hundreds of millions into a company whose core technology was fundamentally flawed. You need a way to rapidly and objectively assess technical risk before committing capital.
スコア内訳
市場シグナル
市場投入
Mid-sized venture capital firms and family offices actively investing in biotech and deep-tech startups
~10,000 investment professionals globally evaluating deep-tech deals
LinkedIn outreach to VC partners and family office managers
$2,000/month per firm
5 pilot partnerships with VC firms running the tool on active deal evaluations within 60 days
MVPの範囲 · 1～2週間
- Build a simple web interface for uploading pitch decks and technical documents
- Implement basic LLM-based extraction of key scientific and technical claims from uploaded documents
- Set up API connections to Semantic Scholar for academic paper search
- Create a basic matching algorithm comparing extracted claims to found literature
- Develop a simple dashboard displaying claims alongside supporting or contradicting references
- Add USPTO patent database integration for cross-referencing technical claims
- Implement a basic risk-scoring algorithm based on the volume of contradicting evidence
- Build a red-flag detection module for common hype patterns identified in the discussion
- Create a one-page summary report format for investment committee review
- Conduct initial pilot test with 2-3 friendly VC firms on historical deals for feedback
差別化
失敗する可能性がある理由
自己反論 — 最も重要な信頼のシグナル
- 1Reason 1 — The scientific verification problem is fundamentally hard and may require domain-specific human expertise that an AI tool cannot reliably replace, leading to false positives that destroy trust.
- 2Reason 2 — VCs may be unwilling to adopt a tool that could be seen as questioning their own judgment or deal-sourcing abilities, creating cultural resistance within investment committees.
- 3Reason 3 — Access to comprehensive scientific and patent databases may be prohibitively expensive or restricted, limiting the tool's ability to perform thorough verification.
エビデンスの概要
AIがこのインサイトをどのように統合したか — 逐語的な引用はありません
Multiple commenters highlighted how major investors failed to independently verify technical claims before committing hundreds of millions, noting that those allocating capital had an obligation to conduct diligence but skipped it. The discussion emphasized the difficulty of distinguishing between legitimate startup optimism and reckless deception, particularly in healthcare versus software. Approximately 5 commenters pointed to systemic gaps in how investors evaluate technical feasibility.
アクションプラン
コードを書く前に、この機会を検証しましょう
推奨する次のステップ
検証する
有望なシグナルあり。ランディングページを作りメール登録を集めてから、開発するか決めましょう。
ランディングページ文案キット
実際のRedditコメントから抽出したコピー、そのまま貼り付けられます
見出し
AI-Powered Technical Due Diligence for VCs
サブ見出し
A SaaS platform that automates deep technical due diligence for investors by cross-referencing startup pitch claims against scientific literature, patents, and clinical trial registries. It flags discrepancies and scores technical risk to prevent funding of companies making unverifiable scientific claims.
ターゲットユーザー
対象：Venture capital firms, family offices, and angel investors evaluating deep-tech, biotech, and hard-tech startups
機能リスト
✓ AI claim extraction from pitch decks and technical documents ✓ Automated cross-referencing against patents and academic papers ✓ Technical risk scoring dashboard ✓ Red-flag detection for hype vs substance patterns ✓ Expert network matching for rapid verification
どこで検証するか
r/HN · front_page にランディングページのリンクを投稿しましょう — そこがこの課題が発見された場所です。
同じテーマの他の機会
AIが関連する議論から自動クラスタリング